
Biosimilars Redefining Therapeutic Access: US & EU Markets on the Brink of $171 Billion Revolution | DataM Intelligence
Biosimilars surge with interchangeable approvals, cost savings, and broad pipeline growth, set to hit $171B by 2033. The next wave of drug affordability is here AUSTIN, TX, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- Biosimilars Are …